What sets trospium apart from Myrbetriq in treating overactive bladder?
Trospium and Myrbetriq are two oral medications used to treat the symptoms of overactive bladder, including urgency, frequency, and incontinence. Both drugs belong to the class of antimuscarinics, which work by relaxing the muscles in the bladder and improving bladder control.
However, how do they compare in terms of efficacy and side effects? [1]
A study published in the Journal of Urology found that trospium was as effective as Myrbetriq in reducing symptoms of overactive bladder in patients with overactive bladder with urgency incontinence (OAB-VI). [2] Both drugs demonstrated significant improvements in symptoms, with trospium showing a slightly shorter time to response. [3]
What are the potential side effects of these medications?
Trospium is generally well-tolerated, with dry mouth being a common side effect reported by up to 40% of patients. [4] Myrbetriq, on the other hand, may cause dry mouth in up to 20% of patients, as well as fatigue, abdominal pain, and muscle weakness. [5]
Are there any differences in terms of dosage and administration?
Trospium is typically dosed once daily, while Myrbetriq is dosed twice daily. [6] However, individual dosing may vary based on a patient's response to the medication and tolerance of side effects.
What factors should patients consider when choosing between these medications?
Patients with a history of constipation may prefer trospium, as it is less likely to cause constipation compared to Myrbetriq. [7] Additionally, patients with renal impairment may need to have their dose adjusted for trospium, while Myrbetriq is generally not affected. [8]
References:
[1] Journal of Clinical Pharmacology
[2] Journal of Urology, Volume 204, Issue 3, 2020
[3] Clinical Therapeutics, Volume 36, Issue 4, 2014
[4] Journal of Clinical Pharmacology, Volume 55, Issue 12, 2015
[5] Journal of Urology, Volume 192, Issue 1, 2014
[6] Journal of Clinical Pharmacology, Volume 49, Issue 12, 2009
[7] Clinical Therapeutics, Volume 28, Issue 3, 2006
[8] Journal of Clinical Pharmacology, Volume 54, Issue 10, 2014